GRAIL (NASDAQ:GRAL) President Sells $674,005.95 in Stock

Key Points

• GRAIL President Joshua Ofman sold 8,865 shares of stock on October 15th for a total of $674,005.95, reducing his ownership stake by 2.23% to approximately 387,932 shares.
• GRAIL's stock saw a significant increase of 14.4% on Thursday, reaching $86.41 with a trading volume of over 2 million shares.
• In its latest earnings report, GRAIL posted a loss of $3.18 earnings per share, missing analysts' expectations, while also reporting revenues of $35.54 million.

GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) President Joshua Ofman sold 8,865 shares of the business's stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $76.03, for a total value of $674,005.95. Following the sale, the president owned 387,932 shares in the company, valued at approximately $29,494,469.96. The trade was a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

GRAIL Trading Up 14.4%

Shares of GRAL stock traded up $10.89 during mid-day trading on Thursday, reaching $86.41. The stock had a trading volume of 2,082,810 shares, compared to its average volume of 1,271,702. The business has a 50-day simple moving average of $44.22 and a 200 day simple moving average of $39.30. GRAIL, Inc. has a 12-month low of $12.76 and a 12-month high of $89.57. The company has a market cap of $3.11 billion, a P/E ratio of -6.59 and a beta of 4.11.

GRAIL (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($3.18) earnings per share for the quarter, missing analysts' consensus estimates of ($3.14) by ($0.04). GRAIL had a negative return on equity of 16.64% and a negative net margin of 329.86%.The business had revenue of $35.54 million for the quarter, compared to analysts' expectations of $37.57 million. Research analysts anticipate that GRAIL, Inc. will post -15.15 EPS for the current year.

Institutional Trading of GRAIL

Institutional investors and hedge funds have recently made changes to their positions in the company. Wealthquest Corp purchased a new stake in GRAIL during the first quarter valued at about $18,247,000. AQR Capital Management LLC lifted its stake in shares of GRAIL by 61.0% in the 1st quarter. AQR Capital Management LLC now owns 1,337,163 shares of the company's stock valued at $33,991,000 after purchasing an additional 506,440 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of GRAIL by 60.4% during the 2nd quarter. Geode Capital Management LLC now owns 757,770 shares of the company's stock worth $38,969,000 after purchasing an additional 285,331 shares during the period. Carnegie Investment Counsel acquired a new stake in GRAIL during the 2nd quarter worth approximately $8,520,000. Finally, Invesco Ltd. increased its position in GRAIL by 259.1% during the 2nd quarter. Invesco Ltd. now owns 218,671 shares of the company's stock worth $11,244,000 after purchasing an additional 157,780 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on GRAL shares. UBS Group set a $75.00 price objective on GRAIL in a research report on Friday, October 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of GRAIL in a report on Wednesday, October 8th. Finally, Canaccord Genuity Group increased their target price on GRAIL from $43.00 to $75.00 and gave the stock a "buy" rating in a research report on Friday, October 3rd. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, GRAIL has an average rating of "Hold" and a consensus price target of $56.67.

About GRAIL

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.